East Syracuse-based Clarity Clinical Research has joined Velocity Clinical Research, the leading international integrated clinical site business. Clarity is now “Velocity Clinical Research Syracuse” after the acquisition at the end of 2021, which has led to an influx of clinical trial opportunities for Central New York.

As part of a large multi-site network, the number of new trials at the Syracuse site has rocketed to include research on diabetes, COPD, vaccines for flu, Lyme disease, respiratory syncytial virus (RSV). It has also expanded its therapeutic areas to offer nonalcoholic steatohepatitis (NASH) and memory studies, including prevention trials and mild Alzheimer’s disease research.

Kristen Stebbins, site manager at Velocity Clinical Research Syracuse, shared her excitement about the acquisition, “By centralizing functions like human resources and business development at the national level, our local staff can spend more time with trial volunteers, ensuring they have an optimum experience when taking part in clinical research.”

Dr. Robert C. Cupelo, principal investigator at Velocity Clinical Research Syracuse, explained why being part a national organization will benefit the local community, “Being able to focus more on patients will speed up how quickly we can develop new drugs. As one of the only clinical research facilities serving Central New York, our growth allows more local residents to get involved in clinical trials to advance medical science. This is particularly vital for individuals with chronic conditions who can now access treatment before it is publicly available.”

The acquisition has resulted in growth at the site, more than doubling the number of staff and tripling the number of active clinical trials.